sur EUROMEDIS GROUPE (EPA:ALEMG)
Euromedis Laboratories: 2026 Half-Year Financial Results
Euromedis Laboratories' financial report for the first half of 2026 reveals an 11.6% increase in revenue, reaching €22.8 million. This growth is attributed to increased sales in France and abroad. Gross profit reached €7.8 million, a 36% increase compared to 2025, primarily due to improved margin management. Net income, including the sale of real estate, amounted to €3.9 million, compared to €0.1 million last year.
Furthermore, the company recorded a provision of €1.4 million related to a tax audit. Despite an anticipated impact on second-half cash flow, the company plans to continue its structural optimizations while navigating an uncertain economic climate.
The outlook for the remainder of 2026 is based on the continuation of the current momentum, although pressures on supply costs remain a challenge.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EUROMEDIS GROUPE